ANTIBODIES TO HUMAN IFN IN J.L.P. PATIENTS TREATED WITH HUMAN IFN

J.L.P. 中的人干扰素抗体

• 批准号: 3804736
• 负责人: J BEKISZ
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3804736
• 关键词: antibody neutralization test; antibody specificity; antibody titering; cross immunity; drug adverse effect; drug screening /evaluation; enzyme linked immunosorbent assay; human papillomavirus; human therapy evaluation; human tissue; immunotherapy; interferons; larynx disorder; lymphoblast; monoclonal antibody; virus related neoplasm /cancer

Six hundred and sixty serum samples from 135 patients treated with human leukocyte alpha interferon (Hu IFN (Le) (New York Blood Center, Melville, N.Y.) for Juvenile Laryngeal Papillomatosis (J.L.P.) were tested for the presence of neutralizing antibodies to the above-mentioned alpha interferon. Eleven samples were found to contain neutralizing antibodies to alpha interferon from the N.Y.B.C. Ten of these contained neutralizing antibodies to human leukocyte ` interferon (Alferon; Interferon Sciences, New Brunswick, N.J.) and nine contained neutralizing antibodies to recombinant ` interferon (Intron A, Schering-Plough, Kenilworth, N.J.). Preliminary data suggest that the eleven neutralization positive samples are all positive in ELISA assays for binding to the same types of interferon which they neutralize but, of course, these assays must be repeated. Also of interest is whether any of the positive samples cross react with any of the human lymphoblastoid components which are purified in our laboratory. Neutralization assays will be performed using the eluates from monoclonal antibody columns from which these components are purified. If any neutralization is seen, the individual components found in that eluate will be assayed.

来自135名患者的660份血清样本